Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.ALPN · Entity 90802 | Chief Medical Officer | January 05, 2023 | January 05, 2023 |
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | Director | January 02, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date January 05, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.24 · Expires 2033-01-04 | Direct | 50,000 |
Reported balance
After 2023-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-05 · Grant · Acquired 50,000 · Balance 50,000 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F2: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
Dermata Therapeutics, Inc.
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2036-01-01 | Direct | 2,500 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,500 · Balance 2,500 F1: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000702 · ownership.xml · derivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 23:58 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001654954-25-000414 · section16.xml · derivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 04, 2024 Filed Jan 6, 2024 02:01 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001654954-24-000296 · section16.xml · derivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-03 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing January 4, 2024. Read SEC document |
| January 05, 2023 Filed Jan 5, 2023 19:32 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 50,000 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0001626199-23-000025 · wf-form4_167296511971794.xml · derivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-04 F1 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2 · derivative.exercise_date: One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 21:06 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock | 10,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013530 · section16.xml · nonDerivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,184 F1 · date: On October 6, 2022, the Reporting Person was granted 10,120 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| August 17, 2022 Filed Aug 18, 2022 17:05 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantStock Option (Right to buy) · Derivative | 160,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0000899243-22-029178 · doc4.xml · derivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-08-16 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option will vest on the one (1)-year anniversary of August 17, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Optionee continuing to be a Service Provider through each such date. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:10 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock, par value $0.0001 per share | 8,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009457 · section16.xml · nonDerivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,064 F1 · shares: On July 7, 2022, the Reporting Person was granted 8,874 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 23:15 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantCommon Stock, par value $0.0001 per share | 5,190 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-22-000566 · dermata_fm4apr72022.xml · nonDerivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,190 F1 · shares: On April 7, 2022, the Reporting Person was granted 5,190 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:24 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000905718-22-000054 · dermata_fm4jan32022.xml · derivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing January 3, 2022. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:43 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001102 · dermata_fm4aug172021.xml · derivative · entry 1 Sandler Andrew Seth · CIK 0001596060 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing September 17, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.